Bionaturis shares start quoting in the continuous system on the MAB

Shares of Bionaturis (BNT-MB), an international reference company developing biological drugs, will start quoting from next 23 June in the continuous system instead of fixing (with two auctions per day) on the MAB. So that, Bionaturis’ shares will be available to buy and sell at any moment of each trading session.

It´s a new achievement after its recent increase of capital with 76% of oversubscription. Since its opening session on the MAB, BNT shares price has increased 330%, while the liquidity of the value has increased progressively.

According to Victor Infante, Bionaturis’ CEO, “this is a new milestone on our path in response to what investors were asking for. We have confidence that this measure will allow new qualified stakeholders who understand the business and want to make history with us to be on board. Trading by the continuous system means opening the door to specialized investment funds, both national and abroad, that will contribute to consolidate our growth”.


Bionaturis’ new shares will start quoting at April 30

The Spanish Alternative Stock Market (MAB, in Spanish) has informed about the starting of quotation of Bionaturis’ new issued shares as a result of the just-finished capital increase.

441.241 new shares will be trading in a record time since the ending of the capital increase last April 24. The operation was fulfilled with an oversubscription of 76%.

For further information, please click here  

Bionaturis fulfilled its 3 million € increase of capital with oversubscription

Bionaturis (BNT-MAB), an international reference company developing biological vaccines, has managed to raise 3.088.687 €, 100% of the recent increase of capital offer. It´s noteworthy that there has been an oversubscription of 76% of the total new issued shares. As a result, 441.241 new shares of a nominal value of 0.05 € each, plus an issue premium of 6.95 € have been subscribed.

It´s important to note that 74% of the final subscription has been issued by old shareholders.

After completing the process, Victor Infante, Bionaturis CEO has stated “from start to finish the whole process has surpassed our expectations. Oversubscription of 76%, the confident of old shareholders and the great potential of the new ones, even the negotiation during the pre-emptive subscription rights in the MAB have been overwhelming. On behalf of all the team we just want to say thank you for trusting in Bionaturis. This proof of confidence encourages us to implement successfully our expansion plan. We will release good news in this sense shortly.”

Purpose of the capital increase

The purpose of the capital increase is to finance the company´s internationalization plan and to undertake further investments.


April 24th, 2014|Press english|0 Comments|

Families bet on the Spanish Stock Market

The last report about Property Distribution of quoted Spanish stocks that is made annually by BME reveals that there are more and more families that decide to invest on the Stock Market. Actually, a fourth part of the shares are now in the hands of these investor families, four points more that only a year ago and the highest percentage since nearly a decade.

This rise has been visible since 2008 and has meant a net invest in quoted shares of more than €16,000 million at 2012. Some of the reasons of that trend are the drop of the real-state sector, the downward adjustments of quotations during the crisis or the possibility of choosing the payment in stocks instead of cash.

Bionaturis (ticker BNT) has been quoting at the MAB since January 2012.

Clik here for more information

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.